Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 61Recruiting 43Completed 27Not yet recruiting 11Terminated 3Withdrawn 1Suspended 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Genitourinary 1

Conditions

Multiple Myeloma 2Prostatic Neoplasms 1

Interventions

pembrolizumab 116Carboplatin 48Nivolumab 46Paclitaxel 35Cyclophosphamide 35Cisplatin 34Gemcitabine 30atezolizumab 25Specimen Handling 25venetoclax 24Pemetrexed 24Magnetic Resonance Spectroscopy 24fludarabine 22Ipilimumab 22Docetaxel 22Bevacizumab 22Biopsy 21Radiotherapy 20Azacitidine 20Fluorouracil 19Dexamethasone 19Radiosurgery 18durvalumab 17Leucovorin 16olaparib 14Trastuzumab 14Cetuximab 14Capecitabine 14fludarabine phosphate 13Lenalidomide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Bortezomib × 1 year × Clear all
NCT00183937 2026-05-15

Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer

University of Southern California

Phase 2 Terminated
15 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

NCT01453088 2026-03-24

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

Hackensack Meridian Health

Phase 2 Terminated
63 enrolled 11 charts
Plasma cell

Multiple Myeloma

NCT05556616 2026-01-29

iinnovate-2

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1 Terminated
15 enrolled 15 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡